![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » RECOJET TEST MARKETED IN INDIA
RECOJET TEST MARKETED IN INDIA
Antares Pharma has announced that initial sales of recombinant human insulin along with Antares Pharma's needle-free injection device, the Medi-Jector VISION, have begun in India under the trade name Recojet. Recojet combines Antares Pharma's VISION needle-free injection technology with recombinant human insulin supplied by Singapore-based SciGen, under the local brand name of Recosulin, and is distributed by Mumbai, India-based Shreya Life Sciences.
PharmaLive
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
18Jul
-
21Oct